Plerixafor Injection

Celrixafor is the Generic version of Mozobil™ (PLERIXAFOR)

On December 15, 2008, the U. S. Food and Drug Administration (FDA) approved plerixafor, solution for subcutaneous injection, (Mozobil™, Genzyme Corp.) for use in combination with granulocyte-colony stimulating factor (G-CSF) to mobilize hematopoietic stem cells to the peripheral blood for collection and subsequent autologous transplantation in patients with non-Hodgkin lymphoma (NHL) and multiple myeloma (MM).

Peripheral blood stem cell mobilization, which is important as a source of hematopoietic stem cells for transplantation, is usually performed using granulocyte colony-stimulating factor (G-CSF), but is ineffective in around 15 to 20% of patients. Combination of G-CSF with Celrixafor (Plerixafor)   increases the percentage of persons that respond to the therapy and produce enough stem cells for transplantation